The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial

Journal of Pediatric Endocrinology & Metabolism : JPEM
Maria Lola Evia-ViscarraJuan Gerardo Reyes-García

Abstract

To compare serum concentrations of inflammatory cytokines, interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), adiponectin, and tumor necrosis factor alpha (TNFalpha), before and after 3 months treatment with metformin in obese adolescents with insulin resistance (IR). This was a randomized, double-blinded, clinical trial of two groups of obese adolescents with IR, aged 9-18 years: a placebo group (n=14) and a metformin group (n=12) who received 500 mg metformin every 12 h for 3 months. Anthropometric and biochemical (metabolic and inflammatory cytokines) assessments were compared at the beginning and end of treatment. After 3 months of treatment, body mass index (kg/m2) was reduced in both groups: placebo group (32.82 +/- 6.37-32.10 +/- 6.52; p=0.011) and metformin group (33.44 +/- 5.82-32.71 +/- 5.77; p=0.015). Serum fasting insulin concentrations (pmol/L) increased in the placebo group (189.45 +/- 112.64-266.06 +/- 167.79; p=0.01) and showed a slight decrease in the metformin group (256.82 +/- 113.89-229.25 +/- 86.53; p=0.64). Adiponectin concentrations (microg/mL) decreased in the placebo group (13.17 +/- 7.31-5.65 +/- 6.69; p=0.02), while these remained stable in the metformin group (8.57 +/- 3.98-7.86 +/- ...Continue Reading

Associated Clinical Trials

Aug 5, 2011·Maria Lola Evia-Viscarra, Maria Lola Evia-Viscarra

Citations

Feb 15, 2013·Cardiovascular Toxicology·Joshua K Salabei, Daniel J Conklin
Sep 4, 2013·The Journal of Clinical Investigation·Michael Pollak
Nov 21, 2012·PloS One·Javier AmpueroManuel Romero-Gómez
Nov 12, 2013·Metabolic Syndrome and Related Disorders·Ali A RizviNicola Abate
Jul 30, 2014·Eating and Weight Disorders : EWD·Laura PalaCarlo Maria Rotella
Mar 13, 2015·Expert Opinion on Therapeutic Targets·Ricardo Ladeiras-LopesAdelino Leite-Moreira
Apr 17, 2013·International Immunopharmacology·Silvana A VielmaM Rita I Young
Apr 27, 2016·International Journal of Obesity : Journal of the International Association for the Study of Obesity·A S KellyJ R Ryder
Mar 24, 2016·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·C O FranciscoA M O Leal
Jul 16, 2016·Circulation Research·Amy R CameronGraham Rena
Dec 5, 2018·European Journal of Clinical Pharmacology·Fuhai HuiQingchun Zhao
Jun 13, 2018·Journal of Lipid Research·W Reid Bolus, Alyssa H Hasty
Aug 29, 2018·Endocrine·Hong-Hong NingShu-Lan Qin
Jun 6, 2020·Therapeutic Advances in Endocrinology and Metabolism·Ruiyang PuNing Cheng
Oct 6, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Phiwayinkosi V DludlaLuca Tiano

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.